[Ip-health] Class Action on Behalf of Shareholders of Novartis AG

[Joana Ramos]

This is a multi-part message in MIME format.
--
[ Picked text/plain from multipart/alternative ]

http://biz.yahoo.com/iw/071101/0323263.html?printer=1

<snip>

The complaint alleges that throughout the Class Period,
Novartis failed to
disclose adverse information regarding the Company's research
into a
potential new cancer drug. Tasigna........

Press Release

Stull, Stull & Brody Announces Class Action on Behalf of Shareholders of Novartis AG
Thursday November 1, 4:45 pm ET

NEW YORK, NY--(MARKET WIRE)--Nov 1, 2007 -- Attorney Advertising. Notice is hereby given
that a class action has been commenced in the United States
District Court
for the District of New Jersey on behalf of an investor
and other similarly
situated purchasers of Novartis AG ("Novartis" or the "Company")
(NYSE:NVS - News) securities between June 14, 2006 and July 17,
2007 (the "Class
Period").

Stull, Stull & Brody has substantial experience representing
employees who
suffered losses from purchases of their employer's stock
in their 401(k)
plans. If you bought Novartis stock through your Novartis
retirement
account and have information or would like to learn more
about these
claims, please contact us.

The complaint charges Novartis and certain of its officers
and directors
with violations of the Securities Exchange Act of 1934.
Novartis engages
in the research, development, manufacture, and sale of health
care
products.

The complaint alleges that throughout the Class Period,
Novartis failed to
disclose adverse information regarding the Company's research
into a
potential new cancer drug. Tasigna, which caused the Company's
shares to
trade at artificially inflated prices during the Class Period.
On July 17,
2007, the Company issued a press release announcing that
the FDA had
requested a three-month extension in the regulatory review
period for
Tasigna. Following the FDA disclosure of the safety data
for Tasigna,
which defendants had known for several months, Novartis
share price
declined from $55.45 to $53.36 in two days.

Plaintiff seeks to recover damages on behalf of all those
who purchased or
otherwise acquired Novartis securities during the Class
Period, which is
between June 14, 2006 through July 17, 2007. If you purchased
or otherwise
acquired Novartis securities during the Class Period, and
either lost money
on the transaction or still hold the securities, you may
wish to join in
the action to serve as lead plaintiff. If you purchased
Novartis securities
during the Class Period, you may request that the Court
appoint you as lead
plaintiff no later than sixty days from October 29, 2007.

A lead plaintiff is a representative party that acts on
behalf of other
class members in directing the litigation. In order to be
appointed lead
plaintiff, the Court must determine that the class member's
claim is
typical of the claims of other class members, and that the
class member
will adequately represent the class. Under certain circumstances,
one or
more class members may together serve as "lead plaintiff."
Your ability to
share in any recovery is not, however, affected by the decision
whether or
not to serve as a lead plaintiff. You may retain Stull,
Stull & Brody, or
other counsel of your choice, to serve as your counsel in
this action.
Stull, Stull & Brody has litigated many class actions
for violations of
securities laws in federal courts over the past 30 years
and has obtained
court approval of substantial settlements on numerous occasions.
Stull,
Stull & Brody maintains offices in New York and Los
Angeles.

If you wish to discuss this action or have any questions
concerning this
notice or your rights or interests with respect to these
matters, please
contact Tzivia Brody, Esq. at Stull, Stull & Brody by
e-mail at
SSBNY@aol.com, by calling
toll-free 1-800-337-4983, or by fax at
212/490-2022, or by writing to Stull, Stull & Brody,
6 East 45th Street,
New York, NY 10017. You can also visit our website at www.ssbny.com.

 Contact:     Contact:
     Tzivia Brody, Esq.
     Stull, Stull & Brody
     Email Contact
     toll-free 1-800-337-4983
     fax at 212/490-2022

----------------------

Joana Ramos, MSW
Cancer Resources & Advocacy
Seattle WA
+1-206-229-2420
http://ramoslink.info/



--